AU2018383669B2 - Peptides and other agents for treating pain and increasing pain sensitivity - Google Patents

Peptides and other agents for treating pain and increasing pain sensitivity Download PDF

Info

Publication number
AU2018383669B2
AU2018383669B2 AU2018383669A AU2018383669A AU2018383669B2 AU 2018383669 B2 AU2018383669 B2 AU 2018383669B2 AU 2018383669 A AU2018383669 A AU 2018383669A AU 2018383669 A AU2018383669 A AU 2018383669A AU 2018383669 B2 AU2018383669 B2 AU 2018383669B2
Authority
AU
Australia
Prior art keywords
seq
magi
peptide
pain
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018383669A
Other languages
English (en)
Other versions
AU2018383669A1 (en
Inventor
Arindam Bhattacharjee
Kerri PRYCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of AU2018383669A1 publication Critical patent/AU2018383669A1/en
Application granted granted Critical
Publication of AU2018383669B2 publication Critical patent/AU2018383669B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • C12Y207/04008—Guanylate kinase (2.7.4.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018383669A 2017-12-13 2018-12-13 Peptides and other agents for treating pain and increasing pain sensitivity Active AU2018383669B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598067P 2017-12-13 2017-12-13
US62/598,067 2017-12-13
PCT/US2018/065545 WO2019118779A2 (en) 2017-12-13 2018-12-13 Peptides and other agents for treating pain and increasing pain sensitivity

Publications (2)

Publication Number Publication Date
AU2018383669A1 AU2018383669A1 (en) 2020-07-02
AU2018383669B2 true AU2018383669B2 (en) 2023-05-18

Family

ID=66820711

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018383669A Active AU2018383669B2 (en) 2017-12-13 2018-12-13 Peptides and other agents for treating pain and increasing pain sensitivity

Country Status (8)

Country Link
US (3) US11535649B2 (https=)
EP (1) EP3723781B1 (https=)
JP (2) JP2021506794A (https=)
CN (1) CN111712252A (https=)
AU (1) AU2018383669B2 (https=)
CA (1) CA3085576A1 (https=)
IL (1) IL275340A (https=)
WO (1) WO2019118779A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085576A1 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
BR112022006862A2 (pt) * 2019-10-10 2022-07-05 Univ New York State Res Found Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2025102083A1 (en) * 2023-11-12 2025-05-15 The Research Foundation For The State University Of New York Compositions and methods for treating pain or for increasing pain sensitivity
WO2025123001A1 (en) * 2023-12-08 2025-06-12 Washington University Targeted protein degradation compositions and methods of use thereof for pain control

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187533B1 (en) * 1996-09-10 2001-02-13 Arch Development Corporation Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (HNF) 1 alpha (α), HNF1β and HNF4α
SI2168984T1 (sl) * 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
EP1252330A2 (en) 1999-11-26 2002-10-30 McGill University Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
US20030216310A1 (en) 2001-05-25 2003-11-20 Thornton Michael B. Transporters and ion channels
US20090087436A1 (en) 2001-07-13 2009-04-02 Myriad Genetics, Incorporated Compositions and methods for treating diseases
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1438584A4 (en) * 2001-10-01 2006-12-27 Buck Inst TARGET-ASSISTED ITERATIVE SCREENING (TAIS), NEW SCREEN FORMAT FOR LARGE MOLECULAR REPERTOIRES
WO2003087768A2 (en) 2002-04-12 2003-10-23 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
WO2005059101A2 (en) 2003-12-12 2005-06-30 Wyeth Novel sodium channel
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005118614A1 (en) * 2004-04-08 2005-12-15 Avigen, Inc. Methods and compositions for treating neuropathic pain
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
JP2010529966A (ja) 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
WO2009006555A2 (en) 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
DK2307035T3 (da) 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
JP2012503619A (ja) 2008-09-26 2012-02-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
EP2275545A1 (en) 2009-07-16 2011-01-19 Julius-Maximilians-Universität Würzburg Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
EP2478002B1 (en) * 2009-09-18 2015-02-25 University Of Houston Small peptide modulators of potassium channel trafficking
WO2012004664A2 (en) * 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
EP2616094B1 (en) 2010-08-12 2017-11-08 NoNO Inc. Treatment of penetrative injury to the brain
WO2012135666A1 (en) 2011-04-01 2012-10-04 University Of Louisiana At Monroe Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
EP2773366B1 (en) * 2011-11-04 2017-03-01 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP2019512015A (ja) * 2016-02-26 2019-05-09 ザ・ジョンズ・ホプキンス・ユニバーシティ 機械的刺激による痛みに関連する電位依存性ナトリウム・チャネルＮａｖ１．１に対する調節薬
CA3085576A1 (en) * 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRYCE KERRI D ET AL: "Functional Regulation of Ion Channels in Dorsal Root Ganglion Neurons by Magi-1: Implications in Pain Signaling", 1 April 2018 (2018-04-01) *

Also Published As

Publication number Publication date
WO2019118779A3 (en) 2019-07-25
US20230046305A1 (en) 2023-02-16
US11535649B2 (en) 2022-12-27
JP2021506794A (ja) 2021-02-22
US20200369726A1 (en) 2020-11-26
EP3723781B1 (en) 2024-12-11
AU2018383669A1 (en) 2020-07-02
EP3723781A4 (en) 2021-07-21
CN111712252A (zh) 2020-09-25
US12077610B2 (en) 2024-09-03
JP2024026109A (ja) 2024-02-28
WO2019118779A2 (en) 2019-06-20
US20250154199A1 (en) 2025-05-15
EP3723781A2 (en) 2020-10-21
CA3085576A1 (en) 2019-06-20
IL275340A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
US12077610B2 (en) Peptides and other agents for treating pain and increasing pain sensitivity
JP2017524382A (ja) 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ
US20250215052A1 (en) Inhibitors of pick1 and uses thereof
Pryce et al. Magi-1 scaffolds NaV1. 8 and Slack KNa channels in dorsal root ganglion neurons regulating excitability and pain
US11236147B2 (en) Methods and compositions for the inhibition of TRPV4
US20160230171A1 (en) Methods for inducing glucose uptake
US20140147440A1 (en) Uses of nanog inhibitors and related methods
DK2904009T3 (en) RELATIONSHIPS FOR TREATING THE REMYELINIZATION BLOCK IN DISEASES RELATED TO THE EXPRESSION OF HERV-W COAT PROTEIN
WO2012068332A2 (en) Methods for treating early stage or mild neurological disorders
JP6306768B2 (ja) 疼痛抑制物質のスクリーニング方法および疼痛の予防または治療用医薬組成物
KR102772298B1 (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
US20240294571A1 (en) Analgesic and anesthetic peptides and other agents
CA3069179A1 (en) Targeting the hdac2-sp3 complex to enhance synaptic function
Pryce Functional Regulation of Ion Channels in Dorsal Root Ganglion Neurons by Magi-1: Implications in Pain Signaling
CN121695274A (zh) 抑郁症的治疗方法和药物组合物
WO2025102083A1 (en) Compositions and methods for treating pain or for increasing pain sensitivity
Heuermann The Role of HCN Channels and TRIP8b in Depression and Epilepsy
Fanous BDNF and the mesocorticolimbic dopamine system: Social stress-induced psychomotor sensitization and social behaviors
JP2018172285A (ja) 細胞内の異常物質蓄積を伴う疾患の治療薬、バイオマーカー、診断薬、並びに、スクリーニング方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)